Angeles Del Pedregal Hospital

Ex-Hacienda el Hospital, Mexico

Angeles Del Pedregal Hospital

Ex-Hacienda el Hospital, Mexico
SEARCH FILTERS
Time filter
Source Type

Talavera J.-O.,Social Security Mexican Institute | Martinez G.,Astrazeneca | Cervantes J.-L.,Angeles Del Pedregal Hospital | Marin J.-A.,Toluca Medical Center | And 6 more authors.
Current Medical Research and Opinion | Year: 2013

Objective:The most prevalent dyslipidemias in Mexico are low high-density lipoprotein (HDL) and high triglyceride (TG) levels. Hypertriglyceridemia (HTG) has been considered an independent risk factor for cardiovascular disease (CVD). The aim of this study was to evaluate the efficacy of rosuvastatin (RSV) in reducing TG levels in Mexican patients. Methods:A randomized, double-blind, double-dummy, parallel-group, placebo-controlled, multicenter, phase IV study was conducted. Patients were of both genders, 18 years old, with basal TG levels between 200 and 800mg/dl, LDL levels 190mg/dl. Patients were randomized to receive rosuvastatin 10mg (Group 1), 20mg (Group 2) or placebo (Group 3) once daily for 8 weeks. Primary efficacy was TG level; secondary efficacy was non-HDL; HDL, low-density lipoprotein (LDL), total cholesterol (TC), Apo (apolipoprotein) A1, and ApoB. Safety data were evaluated up to 30 days after the last dose of medication. The Mann-Whitney U-test was performed to contrast each RSV groups against placebo; p<0.05 was considered significant. Trial registry number is NCT00473655. Results:A total of 334 patients were randomized: Group 1=111, Group 2=112, and Group 3=111. Basal TG median value levels were 278mg/dl, 266mg/dl, 279mg/dl with median reduction (MdR) at 8 weeks of 26.6%, 32.19% and 7.58%, respectively, (Group 1 vs. Group 3 p=0.002, and Group 2 vs. Group 3 p<0.0001). Basal non-HDL values were 179mg/dl, 180mg/dl and 179mg/dl with a MdR of 27%, 32% and 8%, respectively (Group 1 vs. Group 3 p<0.0001, and Group 2 vs. Group 3 p<0.0001); basal LDL vales were 130mg/dl, 130mg/dl and 127mg/dl with MdR 35%, 44% and-4% (Group 1 vs. Group 3 p<0.0001, Group 2 vs. Group 3 p<0.0001); basal ApoB values were 114mg/dl, 115mg/dl and 110.5mg/dl with MdR 25%, 33% and-0.5% (Group 1 vs. Group 3 p<0.0001, Group 2 vs. Group 3 p<0.001). Conclusion:Rosuvastatin 10 and 20mg/day significantly reduced triglycerides and improved atherogenic lipid profile in HTG Mexican patients. The main limitation was the short follow-up time period. © 2013 Informa UK Ltd All rights reserved.


Rodriguez-Fuentes R.,Angeles Del Pedregal Hospital | Esparza E.A.,Angeles Del Pedregal Hospital | MacIas M.P.,Angeles Del Pedregal Hospital | Quiroz-Castro O.,Angeles Del Pedregal Hospital
Journal of Bronchology and Interventional Pulmonology | Year: 2013

The accessory bronchus involving the trachea or main bronchi is very rare. In this report, we present images of an accessory bronchus, detected by computed tomography scan and flexible bronchoscopy. Our patient was suffering from persistent productive cough and had normal chest x-ray. We review the literature to establish relationship between our patient's symptoms and this congenital anomaly. © 2013 Lippincott Williams & Wilkins.


PubMed | Angeles Del Pedregal Hospital
Type: Case Reports | Journal: Journal of bronchology & interventional pulmonology | Year: 2013

The accessory bronchus involving the trachea or main bronchi is very rare. In this report, we present images of an accessory bronchus, detected by computed tomography scan and flexible bronchoscopy. Our patient was suffering from persistent productive cough and had normal chest x-ray. We review the literature to establish relationship between our patients symptoms and this congenital anomaly.

Loading Angeles Del Pedregal Hospital collaborators
Loading Angeles Del Pedregal Hospital collaborators